The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease ; volume:12 ; number:5 ; day:15 ; month:4 ; year:2021 ; pages:1523-1534 ; date:5.2021
Diabetes therapy ; 12, Heft 5 (15.4.2021), 1523-1534, 5.2021
- Urheber
-
Ehlers, Lars Holger
Lamotte, Mark
Monteiro, Sofia
Sandgaard, Susanne
Holmgaard, Pia
Frary, Evan C.
Ejskjaer, Niels
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-021-01040-y
- URN
-
urn:nbn:de:101:1-2021090819132589097658
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ehlers, Lars Holger
- Lamotte, Mark
- Monteiro, Sofia
- Sandgaard, Susanne
- Holmgaard, Pia
- Frary, Evan C.
- Ejskjaer, Niels
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients
Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients
Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients
Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure